Replimune Shares Surge After FDA Resubmission for Advanced Melanoma Therapy
Replimune Soars Upon FDA Resubmission for Advanced Melanoma Drug Last month, investors’ hopes were dashed as Replimune suggested alignment had not yet been reached with the FDA on RP1’s future.…
Roche’s Gazyva Secures FDA Approval for Lupus, Marking Expansion Beyond Cancer
The FDA approval marks Gazyva’s first non-oncology indication, expanding Roche’s presence into autoimmune disease treatment. The anti-CD20 antibody, developed by Roche’s Genentech along with Biogen and already approved for multiple…
Counteracting Complacency in Multiple Myeloma: The Fight Is Far from Over
Despite major therapeutic advances, patients with multiple myeloma continue to face relapse and resistance—demanding renewed focus and innovation. Recent headlines proclaim a ‘potential’ or ‘functional’ cure for multiple myeloma, but…
Hansoh Pharma Presents Phase 2 Data on HS-20089 for Platinum-Resistant Ovarian Cancer at ESMO 2025
The investigational B7-H4–targeted antibody–drug conjugate HS-20089 demonstrates encouraging efficacy and manageable safety in patients with platinum-resistant ovarian cancer. Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK) today announced positive phase…
Fiji Achieves Milestone as the 26th Country to Eliminate Trachoma as a Public Health Concern
The World Health Organization confirms Fiji has eliminated trachoma as a public health problem, marking a major step toward global eye health goals. In a landmark public health achievement, Fiji…
Novartis Kisqali® 5-Year Data Show 28% Reduced Recurrence Risk in Early Breast Cancer
Novartis Kisqali® Shows Sustained Five-Year Benefit in Broad Early Breast Cancer Population Novartis today released results from the five-year analysis of the pivotal Phase III NATALEE trial, confirming the long-term…
CHMP Gives Positive Opinion for Scemblix in Newly Diagnosed CML
CHMP Recommends Scemblix for Newly Diagnosed CML in Europe, Offering Superior Efficacy and Tolerability Novartis has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European…
CHMP Recommends Saphnelo Subcutaneous Use for Lupus in EU
CHMP Recommends Saphnelo Subcutaneous Administration for SLE in the EU, Offering Convenient Self-Administration Option AstraZeneca has announced that its fully human monoclonal antibody Saphnelo (anifrolumab) has received a positive opinion…
CatalYm Shows Promising Phase 2 Results for Visugromab + PD-1 Inhibitor in Neoadjuvant Bladder Cancer at ESMO
CatalYm Unveils Promising Phase 2 GDFATHER-NEO Data: Visugromab Enhances Anti-Tumor Activity with PD-1 Inhibition in Neoadjuvant Muscle-Invasive Bladder Cancer CatalYm, a pioneering biotechnology company recognized globally for its focus on…
Tezspire Wins U.S. Approval for Nasal Polyps
Tezspire Secures U.S. FDA Approval for Chronic Rhinosinusitis with Nasal Polyps, Expanding Its Reach Beyond Severe Asthma AstraZeneca and Amgen have announced that their jointly developed biologic, Tezspire (tezepelumab), has…
Agenus Shows 39% Two-Year Survival with BOT/BAL in Refractory Solid Tumors at ESMO 2025
Agenus Reports Durable Two-Year Survival with BOT/BAL Combination Across Refractory Solid Tumors at ESMO 2025 Agenus Inc. (Nasdaq: AGEN), a biotechnology company recognized for its pioneering work in immuno-oncology, unveiled…
Roche Reveals 2 Phase III Trial Results for Vamikibart in Uveitic Macular Edema
Roche Unveils Promising Phase III Data for Vamikibart in Uveitic Macular Edema (UME), Highlighting Potential as First-in-Class Non-Steroidal Treatment Option Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced pivotal Phase…